Efficacy of levocetirizine in perennial allergic rhinitis (PAR) as measured by the number of comfortable days Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Antihistamines (cetirizine and loratadine) and antileukotriene (montelukast) in the prevention of allergic rhinitis symptoms Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
Combination of montelukast and loratadine provides added benefit for relief of symptoms of seasonal allergic rhinitis (SAR) Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Efficacy and safety of levocetirizine in persistent allergic rhinitis (PER) Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Effect of the leukotriene-receptor antagonists and interval hypoxic trainings (IHT) at children with asthma (BA) and allergic rhinitis (AR) Source: Annual Congress 2008 - Exercise-induced asthma, acute severe asthma and allergic rhinitis in children Year: 2008
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
A comparison of oral loratadine and fluticasone propionate aqueous nasal spray plus oral loratadine in the treatment of atopic cough associated with seasonal allergic rhinitis (SAR) Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005
Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Effects of Omalizumab treatment on nasal symptoms (SNOT score) in patients treated for severe asthma. Source: International Congress 2017 – Asthma management Year: 2017
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Evaluation of fluticasone (flixonase) nasal spray versus beclomethasone (beconase) nasal spray in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Budesonide and loratadine in the treatment of allergic rhinitis in children Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
The effect of topical nasal budesonide (BUD) on Epworth sleepiness scale (ESS), fatigue, and performance in perennial allergic rhinitis (PAR) Source: Eur Respir J 2002; 20: Suppl. 38, 218s Year: 2002